

**GEOVAX LABS, INC.**  
**Condensed Consolidated Statements of Operations Information**  
*(amounts in thousands, except common share information)*

	Three Months Ended March 31,	
	2022	2021
Grant revenues	\$ 82	\$ 110
Operating expenses:		
Research and development	1,331	603
General and administrative	1,179	1,071
	2,510	1,674
Loss from operations	(2,428)	(1,564)
Other income (expense), net	1	1
	\$ (2,427)	\$ (1,563)
Net loss		
	\$ (0.34)	\$ (0.29)
Net loss per common share		
Weighted average common shares outstanding	7,109,473	5,332,058

**Condensed Consolidated Balance Sheet Information**  
*(amounts in thousands, except common share information)*

	March 31, 2022	Dec. 31, 2021
Assets:		
Cash and cash equivalents	\$ 16,258	\$ 11,424
Other current assets	379	205
Total current assets	16,637	11,629
Property and other assets, net	218	168
Total assets	\$ 16,855	\$ 11,797
Liabilities and stockholders' equity		
Total liabilities	\$ 5,501	\$ 7,435
Stockholders' equity	11,354	4,362
Total liabilities and stockholders' equity	\$ 16,855	\$ 11,797
Common shares outstanding	9,449,025	6,381,541